

CURRICULUM VITAE**Dr. Nicolaas Paul Leonard Gerrit Verhoeff****Work Address:**

Kunin-Lunenfeld Applied Research Unit
 Brain Health Complex, 7th Floor, Room 762, Baycrest
 3560 Bathurst Street
 Toronto, Ontario M6A 2E1, Canada
 Email: pverhoeff@klaru-baycrest.on.ca
 Phone: 416-785-2500-x2167
 Fax: 416-785-4230

Profession:

April 2005-present	Associate Professor of Psychiatry (# 1016849) Department of Psychiatry, Geriatric Program, University of Toronto, Toronto, Ontario, Canada
December 2003-present	Staff Psychiatrist, Brain Health Centre, Behavioural Neurology Memory Disorders Clinic, and Geriatric Psychiatry Community Service, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada
July 2001-present	Neuropsychiatry Clinician-Scientist, Kunin-Lunenfeld Applied Research Unit, and Staff Psychiatrist, Geriatric Psychiatry Community Service, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada
April 2001-April 2005	Assistant Professor of Psychiatry (# 1016849) Department of Psychiatry, Geriatric Program, University of Toronto, Toronto, Ontario, Canada
August 1999-July 2001	Clinical Research Fellow Schizophrenia/PET Centre, Clarke Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
July 1998-July 1999	Advanced Resident and Fellow in Addiction Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
July 1994-June 1998	Resident, Department of Psychiatry, (Neuroscience Research Training Program) Yale University School of Medicine, New Haven, Connecticut, United States of America

March 1994-June 1994 Resident, Department of Psychiatry,
Cluster of Patients with Schizophrenia,
Academic Hospital Groningen, Netherlands

March 1993-February 1994 Served as MD and First-Lieutenant,
Dutch Landforces at the Central Section
for Individual Psychosocial Aid.
Worked as clinical psychologist.

Education:

October 2003: Diplomate of the American Board of Psychiatry
and Neurology, Inc., a Member Board of the
American Board of Medical Specialties (# 53130)

September 2003: Passed American Board of Psychiatry and
Neurology Examination Part II

January 2002: Certificate of Registration for Independent
Practice from the College of Physicians and
Surgeons of Ontario (# 74459)

December 2001: Licentiate of the Medical Council of Canada
Name entered in the Canadian Medical Register
(# 91136)

October 2001: Passed Medical Council of Canada Qualifying
Examination Part II (# 9980517)

December 2000: Fellow of the Royal College of Physicians and
Surgeons of Canada(# 556363)

November 2000: Passed Royal College of Physicians and Surgeons
Psychiatry Examination Part II(# 556363)

September 2000: Passed Royal College of Physicians and Surgeons
Psychiatry Examination Part I(# 556363)

May 2000: Passed Medical Council of Canada Qualifying
Examination Part I (# 9980517)

January 2000: Certificate of Registration for Postgraduate
Education from the College of Physicians and
Surgeons of Ontario (# 74459)

October 1999: Physician Licensure in The Netherlands,
European Union (# 29024521601)

September 1999: Passed Medical Council of Canada Evaluating
Examination (# 9980517)

November 1998: Passed American Board of Psychiatry and
Neurology Examination Part I

November 1996: Physician Licensure in Connecticut,
United States of America (# 035708)

February 1996: Passed United States Medical Licensure
Examination Steps 1, 2 and 3 (# 0-505-330-1)

April 1993: PhD Thesis Neurosciences Amsterdam on theme:
'Neuroreceptor Imaging with SPECT',
University of Amsterdam (cum laude)

October 1988: MD by Medical Qualifying Examination (cum laude), Erasmus University Rotterdam

September 1986: Examination for the 'drs.' degree in Medicine, Erasmus University Rotterdam

July 1983: Propaedeutics in Medicine (cum laude), Erasmus University Rotterdam

Research activities:

Most of my research activities have centered around neuroreceptor imaging in vivo with positron emission tomography (PET) or single-photon computerized tomography (SPECT) in patients with neuropsychiatric disorders and in healthy control subjects. The research projects are listed according to the neurochemical transmission systems that have been studied, with further clarification as to which patient groups were involved during which period:

1. Cerebral β -Amyloid imaging with PET in patients with Alzheimer's disease (2001-present) and with SPECT in patients with amyloid angiopathy (1991-1996).
2. Neostriatal dopamine D₂ receptor imaging with PET in patients with schizophrenia and in healthy subjects before and after catecholamine depletion with α -methyl-para-tyrosine (1999-2001), in patients with schizophrenia off and on antipsychotics (1999-2004), and in patients with major depressive disorder (2001-2004), bipolar disorder (1997-2000); with SPECT in patients with Tourette disorder (1990-1994), partial epilepsy (1991-1994), Parkinsonian syndromes (1990-1993), pituitary macroadenomas (1990-1993), migraine (1990-1993), HIV encephalopathy (1990-1991), in patients with schizophrenia off and on antipsychotics (1990-1995), in healthy subjects (1990-1993), and in MPTP-treated and control nonhuman primates (1990-1994); with a planar gamma-camera for dosimetry in healthy subjects (1990-1993); ex vivo in rodents (1988-1991); and in vitro in humans and rodent brain tissues (1988-1991).
3. Extrastriatal dopamine D₂ receptor imaging with SPECT in healthy subjects (1997-2000).
4. Neostriatal dopamine D₁ receptor imaging with PET in healthy subjects before and after catecholamine depletion with α -methyl-para-tyrosine (1999-2001); and with SPECT in healthy subjects (1991-1993).
5. Cerebral serotonin 5-HT_{1A} receptor imaging with PET in patients with Alzheimer's disease (2001-present), frontotemporal dementia (2001-present), and schizophrenia (1999-2003), and in healthy subjects (1999-2001).
6. Cerebral serotonin 5-HT_{2A} receptor imaging with PET in patients with schizophrenia (1999-2000).
7. Cerebral GABA_A-benzodiazepine receptor imaging with SPECT in patients with alcohol dependence (1997-2004), post-traumatic stress disorder (1997-2004), major depressive disorder (1997-2003), schizophrenia (1994-1999), epilepsy (1994-1999), and in healthy subjects off and on benzodiazepines (1988-1999).
8. Cerebral muscarinic acetylcholinergic mACh receptor imaging with SPECT ex vivo in rats (1988-1993).
9. Pituitary somatostatin receptor imaging with SPECT in patients with pituitary adenomas and in healthy subjects (1992-1996).
10. Cerebral blood flow imaging with SPECT in patients with Alzheimer's disease (1988-1992), partial epilepsy (1988-1992), and ischemic stroke (1988-2001).
11. Physiological measurements of early and late asthmatic responses to submaximal exercise challenge before and after nedocromil sodium in patients with intrinsic and extrinsic bronchial asthma (1988-1990).

Awards:

1. Baycrest Centre for Geriatric Care Outstanding Service Award from the Employee Recognition and Rewards Committee Implementation Team at Baycrest Centre for clinical services provided at the Brain Health Centre Memory Disorders Clinic, April 29, 2005. Total amount: \$ 75.00 (Cdn)
2. Alzheimer's Association Travel Fellowship 2004 for the 9th International Conference on Alzheimer's Disease and Related Disorders in Philadelphia, Pennsylvania, USA, July 17-22, 2004. Total amount: \$ 645.00 (US)
3. International College of Geriatric Psychoneuropharmacology (ICGP) International Junior Investigator Award 2003 (provided at the International College of Geriatric Psychoneuropharmacology 3rd Annual Meeting, December 12-14, San Juan, Puerto Rico 2003). Total amount: \$ 2,000.00 (US)
4. American College of Neuropsychopharmacology (ACNP) Travel Award 1998 (sponsored by Bristol-Myers-Squibb and provided at the American College of Neuropsychopharmacology 37th annual meeting, Las Croabas, Puerto Rico 1998). Total amount: \$ 2,000.00 (US)
5. American Psychiatric Association/Lilly Resident Research Award 1998-1999 (provided at the American Psychiatric Association annual meeting in Washington, DC, on Monday May 17th, 1999). Total amount: \$ 1,500.00 (US)
6. Mallinckrodt-Award 1990 (best presentation from the Benelux at the congress of the European Association of Nuclear Medicine in Amsterdam, 1990). Total amount: Hfl. 2,500.00 (Dutch guilders).

Grant support (Principal Investigator):

1. Alzheimer's Association New Investigator Research Grant: from July 1, 2006 - June 30, 2008. Title: β -amyloid PET imaging in Alzheimer's disease. Total amount: \$ 100,000 (US).
2. Scottish Rite Charitable Foundation of Canada's Major Research Grant: from September 30, 2003 - September 29, 2006. Title: Beta amyloid PET imaging in vivo for early detection of Alzheimer's disease. Total amount: \$104,983 (Canadian).
3. Alzheimer Society of Canada Young Investigator Grant: from September 1, 2002 - August 31, 2004. Title: Imaging amyloid plaques with PET in patients with Alzheimer's disease. Total amount: \$ 50,000 (Canadian)
4. University of Toronto Dean's Fund New Staff Grant: From July 1, 2002 - June 30, 2007. Title: Imaging amyloid plaques with PET in a beagle dog model for Alzheimer's disease. Total amount: \$ 10,000 (Canadian)
5. National Alliance for Schizophrenia and Affective Disorders Young Investigator Award: from July 1, 1999 - June 30, 2001. Title: Imaging striatal synaptic dopamine levels and dopamine D₂ receptor binding potential in schizophrenic patients and in control subjects using [¹¹C]raclopride PET. Total amount: \$ 60,000 (US)
6. Ontario Mental Health Foundation Postdoctoral Fellowship: from July 1, 1999 - June 30, 2001. Title: Imaging striatal synaptic dopamine levels and dopamine D₂ receptor binding potential in schizophrenic patients and in control subjects using [¹¹C]raclopride PET. Total amount: \$ 65,300 (Canadian)

Grant support (Collaborator):

1. Alzheimer Society of Canada: from September 1, 2006 - August 31, 2008. Principal investigator: Dr. Angela Troyer, PhD, CPsych. Title: Amnesic Mild Cognitive Impairment: Cognitive and Neural Mechanisms. Total amount: \$149,977 (Canadian).
2. Orphan Medical Inc.: from January 1, 2004 - December 31, 2006. Principal Investigator: Dr. Morris Freedman, MD, FRCPC. Title: Gammahydroxybutyrate in Alzheimer's Disease: Cognitive, Behavioural and EEG Effects. Total amount: \$822,765 (Canadian)
3. CIHR Randomized Controlled Clinical Trials Unit: from October 1, 2002, until September 30, 2005. Principal Investigator: Dr. Robert van Reekum, MD, FRCPC. Title: A Randomized Controlled Trial of the effects of donepezil on cognitive, behavioural, and functional outcome in traumatic brain injury. Total amount: \$ \$334,326 (Canadian)

Functioned as Reviewer for the following Medical Journals:

1. European Journal of Nuclear Medicine (1992)
2. Psychopharmacology (1999)
3. American Journal of Psychiatry (2001)
4. Journal of Neurochemistry (2001)
5. Journal of Neuropsychiatry and Clinical Neurosciences (2000, 2001, 2003)
6. Journal of Psychiatry and Neuroscience (2001, 2002, 2003)
7. NeuroImage (2002)
8. Neuropsychopharmacology (2000)
9. Psychiatry Research: Neuroimaging (2000, 2001, 2002, 2003)
10. Archives of General Psychiatry (2002)
11. American Journal of Geriatric Psychiatry (2003, 2005)
12. Biological Psychiatry (2003)
13. Brain (2004).

PhD committee member for the following PhD students at the University of Toronto:

1. Dr. Christina Siwak, PhD (April 1999 - November 2002). Thesis: Age-related changes in non-cognitive behaviours in a canine model of aging and dementia and therapeutic evaluation of adrafinil and modafinil.
2. Ms. Jennifer Glass, MSc (February 1998 - May 2005). Thesis: Clinical effects of benzodiazepines in the elderly.
3. Ms. Pearl Behl, MSc (September 2004 - July 2006). Thesis: Longitudinal effects of cholinergic therapy on Alzheimer's disease (AD)- a neurobehavioral, structural and functional imaging study.

MSc committee member for the following PhD students at the University of Toronto:

Matthew Parrott (September 2005- January 2007). Thesis: Postprandial memory response in MCI/MCI-like subjects.

External appraiser for the following MSc thesis presentations:

Ms. Shehnaz Moosa, MSc (September 28, 2005). Thesis: Dysfunction of the brain reward system in apathy associated with Alzheimer's disease. Neuroanatomical correlates and evaluation of measures sensitive to changes induced by dextroamphetamine.

Educational activities:

1. Organized from September 1999 until July 2000 the weekly Schizophrenia Research Seminars of the Schizophrenia & Continuing Care Division at the Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
2. Organized from September 2005 until the present the weekly Grand Rounds at the Baycrest Department of Geriatric Psychiatry.
3. Organized as Course Director the KLARU-Baycrest-CAMH-UofT Division of Geriatric Psychiatry Conference "Behavioural Problems in Dementia - Late-Life Depression: Connecting Research and Clinical Care", which was held on October 20, 2006, at the University of Toronto, 89 Chestnut Street, Toronto, Ontario, Canada.
4. Presenting regularly at the following rounds at Baycrest Centre for Geriatric Care (for specific presentations, see Oral Conference Presentations list below):
 - a. Baycrest Centre Grand Rounds
 - b. Evidence Based Clinical Practice Seminars
 - c. Geriatric Psychiatry Seminar Series
 - d. Grand Rounds at the Baycrest Department of Geriatric Psychiatry
 - e. Kunin-Lunenfeld Applied Research Unit Rounds
 - f. Rotman Research Institute Rounds
 - g. Rounds at the Department of Behavioural Neurology.
5. Supervisor of psychiatry resident Dr. Eileen Sloan, MD, PhD, from March 20, 2003, until June 30, 2003.
6. Supervisor of geriatric medicine fellow Dr. Tricia Woo, MD, from July 18, 2003, until July 31, 2003.
7. Supervisor of psychiatry resident Dr. Treena Wilkie, MD, from July 8, 2003, until December 31, 2003.
8. Supervisor of clinical research fellow Dr. Shinichiro Takeshita, MD, PhD, and Neurosurgeon in Japan, from October 17, 2003, until October 16, 2005.
9. Supervisor of psychiatry resident Dr. Michele Korostil, MD, from January 5, 2004, until June 30, 2004.
10. Supervisor of psychiatry resident Dr. Jinous Hamidi, MD, from July 1, 2004, until December 31, 2004.
11. Supervisor of psychiatry resident Dr. Virginia Wesson, MD, from January 1, 2005, until June 30, 2005.
12. Supervisor of clinical research fellow Dr. Kie Honjo, MD, PhD, and Neurologist in Japan, from April 1, 2005, until the present.
13. Supervisor of the following fellows, residents and medical students at the Baycrest Behavioural Neurology Memory Disorders Clinic:
 - a. Dr. Philip Lee, MD, FRCPC (behavioural neurology fellow) from December 1, 2003, until February 15, 2004
 - b. Dr. Yakir Kaufman, MD (behavioural neurology fellow) from December 1, 2003, until June 30, 2004
 - c. Dr. Laura McCabe, MD (PGY-5 psychiatry resident) from December 1, 2003, until December 31, 2003
 - d. Dr. Esther Bui, MD (neurology resident) from January 1-31, 2004
 - e. Dr. Tricia Woo, MD (geriatric medicine fellow) from February 1-28, 2004
 - f. Dr. Andrew Lim, MD (neurology resident) from July 1, 2004, until August 2, 2004
 - g. Dr. Yael Friedman, MD (neurology resident) from August 3, 2004, until August 28, 2004
 - h. Dr. Khalid Hassan, MD (neurology resident) from November 1, 2004, until November 28, 2004
 - i. Dr. Elizabeth Layne, MD (PGY-5 psychiatry resident) from November 29, 2004, until January 2, 2005
 - j. Dr. Mihaela Nicula, MD (geriatric medicine fellow) from January 3, 2005, until January 30, 2005.
 - k. Dr. Nahathai Wongpakaran, MD (geriatric psychiatry fellow from Thailand) from December 2, 2004, until May 31, 2005 (observer status only).
 - l. Dr. Ling Yap, MD (geriatric psychiatry fellow from Singapore) on

- April 21, 2005 (observer status only).
- m. Dr. Daniel Martinez, MD (geriatric medicine fellow from Argentina) on May 6, 2005 (observer status only).
 - n. Dr. Marcelo Blacutt, MD (geriatric medicine fellow from Chile) from June 9, 2005, until June 30, 2005.
 - o. Dr. Vincenzo Santo Basile, MD (neurology resident) from September 1, 2005, until October 2, 2005.
 - p. Dr. Thirungalal Yogaparan, MD (geriatric medicine fellow from Sri Lanka and the USA) from November 1, 2005, until December 31, 2005.
 - q. Dr. Diyana Docheva, MD (geriatric medicine fellow from Bulgaria) on April 11, 2006.
 - r. Dr. Fabricio Joao Pio, MD, (neurology fellow from Brazil) from April 25, 2006, until May 31, 2006.
 - s. Dr. Jiwon Oh, MD (neurology resident) from September 12, 2006, until September 26, 2006.
 - t. Dr. Yael Perez, MD (neurology resident) from October 10, 2006, until October 27, 2006.
 - u. Dr. Suvendrini Lena, MD (neurology resident) from November 20, 2006, until November 22, 2006.
 - v. Dr. Phil Gerretsen, MD (4th year medical student from McMaster University, Hamilton, Ontario) from January 9, 2007, until January 19, 2007.
 - w. Dr. Maria Luisa Pio-Ferreira (4th year medical student from Brazil) on January 16, 2007.

Membership of the following professional organizations:

1. American Psychiatric Association (Member # 80011)
2. Canadian Medical Association (Member # 120718)
3. Ontario Medical Association (Member # 079-4834)
4. Canadian Medical Protective Association (Member # 1001169)
5. Scientific Review Board of the Institute for the Study of Aging

Membership of the following professional committees:

1. European Association of Nuclear Medicine Neuroimaging Committee.
2. National Institutes of Health - National Institute of Aging Review Committee member for a "reverse" site visit from July 29-30, 2004, in Bethesda, MD, USA, to review a Program Project Grant application by the University of Pittsburgh School of Medicine on behalf of Dr. Steven DeKosky, MD, PhD: "In Vivo PIB PET Amyloid Imaging: Normals, MCI & Dementia."
3. National Institutes of Health - National Institute of Aging Review Committee member for a "reverse" site visit from November 2-3, 2004, in Bethesda, MD, USA, to review a Program Project Grant application by the University College of Los Angeles on behalf of Dr. Gary Small, MD: "Amyloid Imaging in Aging."

References:

Dr. Shitij Kapur, MD, FRCPC, PhD
Canada Research Chair in Schizophrenia and Therapeutic Neuroscience
Vice President Research, Centre for Addiction and Mental Health
Professor of Psychiatry, University of Toronto
Research Scientist, PET Centre
Centre for Addiction and Mental Health, ARF Site
33 Russell Street, Toronto, Canada M5S 2S1
Telephone: 416-979-6890
Fax: 416-260-4206
E-mail: Shitij.Kapur@camh.net

Professor Robert B. Innis, MD, PhD
Chief, Molecular Imaging Branch
NIMH; Bldg. 1 Rm. B3-07
1 Center Drive MSC 0135
Bethesda, MD 20892-0135, USA
Email: robert.innis@nih.gov

Professor P.J. Ell, MSc, MD, PhD, MRCP, MRCRad
Director, Institute of Nuclear Medicine
The University College & Middlesex School of Medicine
The Middlesex Hospital
W1T 3AA London, United Kingdom/England, European Union
Telephone: +44 20-7631 1066
E-mail: p.ell@nucmed.ucl.ac.uk
Fax: +44 20-7436 0603.

Dr. E.A. van Royen, MD, PhD
Professor emeritus in nuclear medicine at the University of Amsterdam
Chairman of the Board
Rijnland Ziekenhuis
Simon Smitweg 1
NL 2353 GA Leiderdorp, The Netherlands, Europe
Telephone: 01131-71-5454440
E-mail: ERoyen@rijnland.nl

Dr. Masanori Ichise, MD, FRCPC
Molecular Imaging Branch
National Institute of Mental Health
Building One, Room B3-10
1 Center Dr. MSC 0135
Bethesda, Maryland 20892-0135, USA
E-mail: MICHISE@PARTNERS.ORG

Dr. Amit Anand, MBBS, FRANZCP
Assistant Professor of Psychiatry
Department of Psychiatry,
Indiana University School of Medicine,
University Hospital,
Indianapolis, Indiana 46202, USA
E-mail: aanand@iupui.edu

PUBLICATIONS:Juried or refereed journal articles, first author:

1. **Verhoeff NPLG.** Amyloid imaging in vivo: implications for Alzheimer's disease management. *Dementia Forum* 2007; issue 2: 9-13.
2. **Verhoeff NPLG.** Antidepressants: mechanism of action. *Geriatrics and Aging* 2005; 8 (8, Supplement): 13-17.
3. **Verhoeff NPLG.** Acetylcholinergic neurotransmission and the β -amyloid cascade: implications for Alzheimer's disease. *Expert Rev Neurotherapeutics* 2005; 5(2): 277-284.
4. **Verhoeff NPLG,** Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S. In vivo imaging of Alzheimer disease β -amyloid with [11 C]SB-13 PET. *Am J Geriatr Psychiatry* 2004; 12: 584-595.
5. **Verhoeff NPLG.** Do NSAIDs reduce the risk of developing AD? *CAGP Bulletin* 2003; 10 (2): 14-15.
6. **Verhoeff NPLG,** Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L, Rui Q, Zipursky RB, Kapur S. Effects of catecholamine depletion on D_2 receptor binding, mood and attentiveness in humans: a replication study. *Pharmacol Biochem Behav* 2003; 74: 425-432.
7. **Verhoeff NPLG,** Hussey D, Lee M, Christensen BK, Papatheodorou G, Zipursky RB, Kapur S. Effects of catecholamine depletion on D_2 receptor binding and mood in healthy humans. *Brain and Cognition* 2003; 51: 200-202.
8. **Verhoeff NPLG.** Pharmacotherapy of agitation and psychotic symptoms in Alzheimer's disease. *Expert Rev Neurotherapeutics* 2002; 2: 655-664.
9. **Verhoeff NPLG,** Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S. Dopamine depletion results in increased neostriatal D_2 , but not D_1 , receptor binding in humans. *Mol Psychiatry* 2002; 7: 322-328.
10. **Verhoeff NPLG,** Tauscher J, Jones C, Hussey D, Lee M, Papatheodorou G, Wilson AA, Houle S, Kapur S. Dopamine depletion results in increased neostriatal D_2 receptor binding in humans. *Mol Psychiatry* 2002; 7: 233.
11. **Verhoeff NPLG,** Kapur S. Neuroimaging and antipsychotics. *J Pharmacy Practice* 2001; 14: 332-340.
12. **Verhoeff NPLG.** Transportadores e síntese pré-sináptica de dopamina em síndromes parkinsonianas. *Rev Bras Psiquiatr* 2001; 23 (Supl I): 50-54.
13. **Verhoeff NPLG.** Imaging of dopaminergic transmission in neuropsychiatric disorders. *Curr Opin Psychiatry* 2001; 14: 227-239.
14. **Verhoeff NPLG,** Kapur S, Hussey D, Lee M, Christensen B, Papatheodorou G, Zipursky RB. A simple method to measure baseline occupancy of neostriatal dopamine D_2 receptors by dopamine in vivo in healthy subjects. *Neuropsychopharmacology* 2001; 25: 213-223.
15. **Verhoeff NPLG,** Meyer JH, Kecojevic A, Hussey D, Lewis R, Tauscher J, Zipursky RB, Kapur S. A voxel-by-voxel analysis of [18 F] setoperone PET data shows no substantial serotonin 5-HT $_{2A}$ receptor changes in schizophrenia. *Psychiatry Res Neuroimaging* 2000; 99: 123-135.
16. **Verhoeff NPLG.** Radiotracer imaging of dopaminergic transmission in

- neuropsychiatric disorders. *Psychopharmacology* 1999; 147: 217-249.
17. **Verhoeff NPLG**, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB. [¹²³I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. *Psychiatry Res Neuroimaging* 1999; 91: 163-173.
 18. **Verhoeff NPLG**, Petroff OAC, Hyder F, Zoghbi SS, Fujita M, Rajeevan N, Rothman DL, Seibyl JP, Mattson RH, Innis RB. Effects of vigabatrin on the GABA-ergic system as determined by [¹²³I]iomazenil SPECT and GABA MRS. *Epilepsia* 1999; 40: 1433-1438.
 19. **Verhoeff NPLG**. Neuroreceptor ligand imaging by Single Photon Emission Computerised Tomography (SPECT). *Nucl Geneeskd Bull* 1993; 15: 71-74.
 20. **Verhoeff NPLG**, Bekier A, Beer HF, Schubiger PA, Fennema P, Van Royen EA. ¹²³I-SCH 23982 is not suitable for dopamine D1 receptor imaging in vivo in the human brain. *Nucl Med Commun* 1993; 14: 137-144.
 21. **Verhoeff NPLG**, Bemelman FJ, Wiersinga WM, Van Royen EA. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. *Eur J Nucl Med* 1993; 20: 555-561.
 22. **Verhoeff NPLG**, Bobeldijk M, Van Breukel AIM, Van Vlies B, Maas MAW, Boer GJ, Feenstra MGP, Erdtsieck-Ernste E, DeBruin K, Olivier G, Van Royen EA. In vitro and in vivo binding of muscarinic cholinergic receptors with ¹²³I-Iododexetimide in rat brain and heart. *Nucl Geneeskd Bull* 1993; 15: 22-27.
 23. **Verhoeff NPLG**, Busemann Sokole E, Stabin M, Hengst D, Kung HF, Van Royen EA, Janssen AGM. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. *Eur J Nucl Med* 1993; 20: 747-752.
 24. **Verhoeff NPLG**, Busemann Sokole E, Hengst D, Stubbs JB, Van Royen EA. Dosimetry of iodine-123 iomazenil in humans. *Eur J Nucl Med* 1993; 20: 580-584.
 25. **Verhoeff NPLG**, Erbas B, Kapucu O, Busemann Sokole E, Blok H, Van Royen EA. Quantification of central benzodiazepine receptor binding potential in the brain with ¹²³I-iomazenil SPECT: technical and interobserver variability. *Nucl Med Commun* 1993; 14: 634-643.
 26. **Verhoeff NPLG**, Kapucu O, Sokole-Busemann E, Van Royen EA, Janssen AGM. Estimation of Dopamine D2 receptor Binding Potential in the Striatum with Iodine-123-IBZM SPECT: Technical and Interobserver Variability. *J Nucl Med* 1993; 34: 2076-2084.
 27. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Stam J, Roolker L, Wiggerts HO, Beer HF. Dynamic studies of the binding of ¹²³I-Iomazenil to central benzodiazepine receptors in healthy volunteers. *Nucl Geneeskd Bull* 1993; 15: 58-60.
 28. **Verhoeff NPLG**, Visser WH, Ferrari MD, Saxena PR, Van Royen EA. Dopamine D2-receptor imaging with ¹²³I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? *Cephalalgia* 1993; 13: 325-329.
 29. **Verhoeff NPLG**, Aldenkamp AP, Overweg J, Van Royen EA, Verbeeten B Jr, Weinstein HC. Memory complaints, memory disorders and focus localization in patients with partial epilepsy. *Seizure* 1992; 1: 149-156.
 30. **Verhoeff NPLG**, Büll U, Costa DC, Kirsch G, Lottes G, Moretti JL, Podreka

- I, Schober O, Van Royen EA. Basics of and Recommendations for Brain SPECT. Nucl Med 1992; 31: 114-131.
31. **Verhoeff NPLG**, Weinstein HC, Aldenkamp AP, Overweg J, Van Royen EA, Verbeeten B Jr. Focus localization in patients with partial epilepsy with $^{99}\text{Tc}^{\text{m}}$ -HMPAO SPECT under continuous surface EEG monitoring. Nucl Med Commun 1992; 13: 127-136.
 32. **Verhoeff NPLG**. Hersenfunctieonderzoek met behulp van isotopen. Medical Technology 1991; 9: 12-15.
 33. **Verhoeff NPLG**. Pharmacological implications for neuroreceptor imaging. Review article. Eur J Nucl Med 1991; 18: 482-502.
 34. **Verhoeff NPLG**, Brücke T, Podreka I, Bobeldijk M, Angelberger P, Van Royen EA. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with ^{123}I -IBZM using the rotating gamma camera. Nucl Med Commun 1991; 12: 687-697.
 35. **Verhoeff NPLG**, Costa DC, Ell PJ, Toone B, Palasidou E, Cullum ID, Bobeldijk M, Miller R, Syed GMS, Barrett JJ, Soricelli A, Van Royen EA. Dopamine D2-receptor imaging with dynamic I-123 IBZM SPET in patients with schizophrenia or HIV encephalopathy. Nucl Geneesk Bull 1991; 13: 67-69.
 36. **Verhoeff NPLG**, Bobeldijk M, Feenstra MGP, Boer GJ, Maas MAW, Erdtsieck-Ernste E, De Bruin K, Van Royen EA. In vitro and in vivo dopamine D2-receptor binding with ^{123}I -S(-)iodobenzamide (^{123}I -IBZM) in rat and human brain. Nucl Med Biol 1991; 18: 837-846.
 37. **Verhoeff NPLG**, Van Royen EA, Ell PJ, Costa DC, Hasler PH, Schubiger PA. Benzodiazepine receptor density in human brain measured in vivo with ^{123}I -Iomazenil SPECT. Nucl Geneesk Bull 1991; 13: 27-29.
 38. **Verhoeff NPLG**, Van Kanten J, Van der Zant FM, Van Royen EA, Weinstein H, Limburg M. A comparison of Tl-201-DDC and Tc-99m-HMPAO SPECT in patients with ischemic stroke or dementia. Nucl Geneesk Bull 1990; 12: 104-106.
 39. **Verhoeff NPLG**, Speelberg B, Van den Berg NJ, Oosthoek CHA, Stijnen T. Real and Pseudo Late Asthmatic Reactions after Submaximal Exercise Challenge in Patients with Bronchial Asthma. A New Definition for Late Asthmatic Responses after Exercise Challenge. Chest 1990; 98: 1194-1199.

Juried or refereed journal articles, co-author:

1. Chow TW, Binns MA, Freedman M, **Verhoeff NPLG**, Stuss DT, Ramirez J, Black S. Neuropsychiatric symptoms in frontotemporal degeneration do not correlate with atrophy. Neurology 2007; Original Research Article, submitted for publication.
2. Zipursky RB, Meyer JH, **Verhoeff NPLG**. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 2007; Review Article, in press.
3. Chow TW, Takeshita S, Honjo K, Pataky CE, St. Jacques PL, Kusano ML, Caldwell CB, Ramirez J, Black S, **Verhoeff NPLG**. Comparison of manual and semi-automated delineation of regions of interest for radioligand PET imaging analysis. BMC Nucl Med. 2007 Jan 29;7(1):2 [Epub ahead of print]
4. Lanctôt KL, Hussey DF, Herrmann N, Black SE, Wilson AA, Houle S, Kozloff N, **Verhoeff NPLG**, Kapur S. A PET study of serotonin 5-HT_{1A} receptor binding potential in Alzheimer's disease. Am J Geriatr Psychiatry 2007; Original Research Article, in press.

5. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, **Verhoeff NPLG**, Wilson AA, Houle S. Elevated putamen D₂ receptor binding potential in major depression with motor retardation: an [¹¹C]raclopride positron emission tomography study. *Am J Psychiatry* 2006; 163(9): 1594-1602.
6. Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O'Malley S, Baldwin R, Jatlow P, **Verhoeff NPLG**, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. *Arch Gen Psychiatry* 2005; 62(8): 877-88.
7. Takeshita S, Kurisu K, Trop L, Arita K, Akimitsu T, **Verhoeff NPLG**. Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems. *Neurosurg Rev* 2005; 28(3): 179-186.
8. Tauscher J, Hussain T, Agid O, **Verhoeff NPLG**, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S: Equivalent occupancy of dopamine D₁ and D₂ receptors differentiates clozapine from other atypicals. *Am J Psychiatry* 2004; 161: 1620-1625.
9. Rapoport M, **Verhoeff NPLG**, van Reekum R. Traumatic Brain Injury and Dementia. *Canadian Alzheimer Disease Review* 2004; 7(2): 4-8.
10. Fujita M, Southwick SM, DeNucci C, Zoghbi SS, Dillon MS, Baldwin RM, Bozkurt A, Kugaya A, **Verhoeff NPLG**, Seibyl JP, Innis RB. Central Type Benzodiazepine Receptors in Gulf War Veterans with Post-Traumatic Stress Disorder. *Biol Psychiatry* 2004; 56: 95-100.
11. Kugaya A, Sanacora G, **Verhoeff NPLG**, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB. Cerebral benzodiazepine receptors in depressed patients measured with [¹²³I]iomazenil SPECT. *Biol Psychiatry* 2003; 54: 792-799.
12. Ono M, Wilson A, Nobrega J, Westaway D, **Verhoeff NPLG**, Zhuang ZP, Kung MP, Kung HF. ¹¹C-Labeled Stilbene Derivates as Aβ-aggregate-specific PET Imaging Agents for Alzheimer's disease. *Nucl Med Biol* 2003; 30: 565-571.
13. Tauscher J, Kapur S, **Verhoeff NPLG**, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Kasper S, Zipursky RB. Brain Serotonin 5-HT_{1A} Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [¹¹C]WAY-100635. *Arch Gen Psychiatry* 2002; 59: 514-520.
14. Tauscher J, **Verhoeff NPLG**, Christensen B, Hussey D, Meyer JH, Kecojevic A, Javanmard M, Kasper S, Kapur S. Serotonin 5-HT_{1A} Receptor Binding Potential Declines with Age as Measured by [¹¹C]WAY-100635 and PET. *Neuropsychopharmacology* 2001; 24: 522-530.
15. Varrone A, Fujita M, **Verhoeff NPLG**, Zoghbi SS, Baldwin RM, Rajeevan N, Charney DS, Seibyl JP, Innis RB. Test-retest reproducibility of extrastriatal Dopamine D₂ Receptor Imaging with [¹²³I]Epidopride SPECT in Humans. *J Nucl Med* 2000; 41: 1343-1351.
16. Anand A, **Verhoeff NPLG**, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. *Am J Psychiatry* 2000; 157: 1108-1114.
17. Fujita M, **Verhoeff NPLG**, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, Anderson GM, Seibyl JP, Innis RB. Imaging extrastriatal dopamine D₂ receptor occupancy by endogenous dopamine in healthy humans. *Eur J*

Pharmacol 2000; 387: 179-188.

18. Fujita M, Seibyl JP, **Verhoeff NPLG**, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS, Innis RB. Kinetic and Equilibrium Analyses of [¹²³I]Epidopride Binding to Striatal and Extrastriatal Dopamine D₂ Receptors. *Synapse* 1999; 34: 290-304.
19. Ichise M, Fujita M, Seibyl JP, **Verhoeff NPLG**, Baldwin RM, Zoghbi SS, Rajeevan N, Charney DS, Innis RB. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D₂ receptor binding with [¹²³I]epidopride SPECT. *J Nucl Med* 1999; 40: 1902-1912.
20. Fujita M, Woods SW, **Verhoeff NPLG**, Abi-Dargham A, Baldwin RM, Zoghbi SS, Soares JC, Jatlow PA, Krystal JH, Rajeevan N, Charney DS, Seibyl JP, Innis RB. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. *Eur J Pharmacol* 1999; 368: 161-172.
21. Van Royen EA, **Verhoeff NPLG**, Meylaerts SAG, Miedema AR. Indium-111-DTPA-Octreotide Uptake Measured in Normal and Abnormal Pituitary Glands. *J Nucl Med* 1996; 37: 1449-1451.
22. Bornebroek M, Verzijlbergen JF, Haan J, Van Scheyen EJ, **Verhoeff NPLG**, Pauwels EK, Roos RA. potential for imaging cerebral amyloid deposits using ¹²³I-labelled serum amyloid P component and SPET. *Nucl Med Commun* 1996; 17: 929-933.
23. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, **Verhoeff NPLG**, Kerwin RW. Dopamine D₂ receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride - an ¹²³I-IBZM single photon emission tomography (SPET) study. *Psychopharmacology* 1995; 117: 55-61.
24. George MS, Robertson MM, Costa DC, Ell PJ, Trimble MR, Pilowsky LS, **Verhoeff NPLG**. D₂ receptor availability in Tourette's Syndrome. *Psychiatry Res: Neuroimaging* 1994; 55: 193-203.
25. Pedro BM, Pilowsky LS, Costa DC, Hemsley DR, Ell PJ, **Verhoeff NPLG**, Kerwin RW, Gray NS. Stereotypy, schizophrenia and dopamine D₂ receptor binding in the basal ganglia. *Psychol Med* 1994; 24: 423-429.
26. Pilowsky LS, Costa DC, Ell PJ, **Verhoeff NPLG**, Murray RM, Kerwin RW. D₂ Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients. An ¹²³I-IBZM Single Photon Emission Computerised Tomography Study. *Br J Psychiatry* 1994; 164: 16-26.
27. Ring HA, Trimble MR, Costa DC, Moriarty J, **Verhoeff NPLG**, Ell PJ. Striatal Dopamine Receptor Binding in Epileptic Psychoses. *Biol Psychiatry* 1994; 35: 375-380.
28. Vermeulen RJ, Drukarch B, **Verhoeff NPLG**, Goosen C, Sahadat MCR, Wolters ECh, Van Royen EA, Stoof JC. No Direct Correlation Between Behaviorally Active Doses of the Dopamine D₂ Agonist LY 171555 and Displacement of [¹²³I]IBZM as Measured with SPECT in MPTP Monkeys. *Synapse* 1994; 17: 115-124.
29. Assies J, **Verhoeff NPLG**, Bosch DA, Hofland LJ. Intracranial dissemination of a macroprolactinoma. *Clin Endocrinol*; 1993; 38: 539-546.
30. Van Royen EA, **Verhoeff NPLG**, Speelman JD, Wolters EChMJ, Kuiper MA, Janssen AGM. Multiple System Atrophy and Progressive Supranuclear Palsy.

- Diminished Striatal D₂ Dopamine Receptor Activity Demonstrated by ¹²³I-IBZM Single Photon Emission Computed Tomography. Arch Neurol 1993; 50: 513-516.
31. Pilowsky LS, Costa DC, Ell PJ, Murray RM, **Verhoeff NPLG**, Kerwin RW. Preliminary communication. Antipsychotic medication, D₂ dopamine receptor blockade and clinical response: a ¹²³I IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23: 791-797.
 32. Kwa VI, Weinstein HC, Posthumus Meyjes FE, Van Royen EA, Bour LJ, **Verhoeff NPLG**, Ongerboer de Visser BW. Spectral Analysis of the EEG and ^{99m}Tc-HMPAO SPECT-Scan in Alzheimer's Disease. Biol Psychiatry 1993; 33: 100-107.
 33. Costa DC, George MS, Ell PJ, Pilowsky L, **Verhoeff NPLG**, Robertson MM. Dopamine D₂ receptor availability in patients with Gilles de la Tourette syndrome studied with SPET. In: Schmidt HAE, Höfer R, eds. Nuclear Medicine in Research and Practice. European Nuclear Medicine Congress, Vienna, September 1-5, 1991. Schattauer Stuttgart-New York. Nucl Med 1992; Suppl 28: 414-417.
 34. Speelberg B, **Verhoeff NPLG**, Van den Berg NJ, Oosthoek CHA, Van Herwaarden CLA, Bruynzeel PLB. Nedocromil sodium inhibits the early and late asthmatic response to exercise. Eur Respir J 1992; 5: 430-437.
 35. Pilowsky LS, Costa DC, Ell PJ, Murray RM, **Verhoeff NPLG**, Kerwin RW. Clozapine, single photon emission tomography, and the D₂ dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199-202.
 36. Ring HA, Trimble MR, George MS, Costa DC, **Verhoeff NPLG**, Ell PJ. Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psychiatr 1992; 55: 758-761.
 37. Schubiger PA, Hasler PH, Beer-Wohlfahrt H, Bejier A, Oettli R, Cordes M, Ferstl F, Deisenhammer E, De Roo M, Moser E, Nitzsche E, Podreka I, Riccabona G, Bangerl I, Schober O, Bartenstein P, Van Rijk P, Van Isselt JW, Van Royen EA, **Verhoeff NPLG**, Haldemann R, Von Schultess GK. Evaluation of a multicentre study with Iomazenil- a benzodiazepine receptor ligand. Nucl Med Commun 1991; 12: 569-582.
 38. Bobeldijk M, **Verhoeff NPLG**, Vekemans JAJM, Buck HM, Van Doremalen PAMP, Van Hoof JJ, Janssen AGM. A simple and high-yield synthesis of (S)-BZM, (R)-BZM and (S)-IBZM for the preparation of (S)-¹²³I-IBZM. J Lab Comp Radiopharm 1990; 28: 1247-1256.
 39. Costa DC, **Verhoeff NPLG**, Cullum ID, Ell PJ, Syed GMS, Barrett J, Palazidou E, Toone B, Van Royen EA, Bobeldijk M. In vivo characterisation of 3-iodo-6-methoxybenzamide ¹²³I in humans. Eur J Nucl Med 1990; 16: 813-816.
 40. Speelberg B, **Verhoeff NPLG**, Van den Brink WT. The prevalence of the early and late asthmatic reaction after exercise in patients with intrinsic and extrinsic asthma. Agents Actions Suppl 1989; 28: 375-378.
 41. Speelberg B, Van den Berg NJ, Oosthoek CHA, **Verhoeff NPLG**, Van den Brink WTJ. Immediate and late asthmatic responses induced by exercise in patients with reversible airflow limitation. Eur Respir J 1989; 2: 402-408.

Book chapters, first author:

1. **Verhoeff NPLG**. Ligands for neuroreceptor imaging by positron or single-photon emission tomography. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd Edition. Churchill Livingstone, New York, NY, USA 2004: 1275-1294.
2. **Verhoeff NPLG**, Wilson AA, Kung HF, Hussey D, Trop L, Houle S. •-Amyloid imaging in vivo and its possible implications for Alzheimer's disease. In: Otte A, Audenaert K, Peremans K, Van Heeringen K, Dierckx RA, eds. Nuclear Medicine in Psychiatry. Springer Verlag, Heidelberg, Germany, European Union 2004: 191-199.
3. **Verhoeff NPLG**, Kapur S. Imaging antipsychotic action at dopamine receptors. In: Sidhu A, Vernier P, Laruelle M, eds. Dopamine Receptors and Transporters. 2nd Edition. Marcel Dekker, Inc., New York, NY, USA 2003: 683-703.
4. **Verhoeff NPLG**. Ligands for neuroreceptor imaging by single photon emission tomography (SPET) or positron emission tomography (PET). In: Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. 2nd Edition. Churchill Livingstone, New York, NY, USA 1998: 521-562.
5. **Verhoeff NPLG**. Benzodiazepine brain SPECT: clinical application. In: Society of Nuclear Medicine 1998 Handout Book Wednesday & Thursday Courses. 45th Annual Meeting. Society of Nuclear Medicine, Reston, VA, USA 1998: 100-104.
6. **Verhoeff NPLG**, Booij J, Innis RB, Van Royen EA. Neuroreceptor ligand imaging by SPECT in Parkinsonian syndromes. In: De Deyn PP, Dierckx RA, Alavi A, Pickut BA, eds. A textbook of SPECT in Neurology and Psychiatry. John Libbey Publishers, London, UK, European Union 1997: 149-165.
7. **Verhoeff NPLG**, Speelman JD, Kuiper MA, Van Royen EA, Kapucu O, Boer GJ, Janssen AGM, Wolters ECh. Clinical Significance of dopamine D2-receptor imaging with ¹²³I-iodobenzamide SPECT in patients with Parkinsonian syndromes. In: De Deyn PP, Dierckx RA, Alavi A, Pickut BA, eds. A textbook of SPECT in Neurology and Psychiatry. John Libbey Publishers, London, UK, European Union 1997: 167-179.
8. **Verhoeff NPLG**. Neuroimaging in Schizophrenia. In: Grünwald F, Kasper S, Biersack HJ, Möller HJ. Brain SPECT Imaging in Psychiatry. Walter de Gruyter, New York, NY, USA 1995: 163-174.
9. **Verhoeff NPLG**. Ligands for neuroreceptor imaging by single photon emission tomography (SPET) or positron emission tomography (PET). In: Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. 1st Edition. Churchill Livingstone, New York, NY, USA 1994: 483-518.
10. **Verhoeff NPLG**. Imaging neurotransmission and neuroreceptors - physiological and pharmacological basis. In: Costa DC, Morgan GF, Lassen NA, eds. New Trends in Nuclear Neurology and Psychiatry. John Libbey & Company Ltd., London, UK, European Union 1993: 25-36.
11. **Verhoeff NPLG**. Neuroreceptor ligand imaging by Single Photon Emission Computerised Tomography (SPECT). Thesis University of Amsterdam, The Netherlands, European Union 1993.
12. **Verhoeff NPLG**, Bobeldijk M, Van Breukel AIM, Van Vlies B, Maas MAW, Boer GJ, Feenstra MGP, Erdtsieck-Ernste E, DeBruin K, Olivier G, Van Royen EA. In vitro and in vivo binding of muscarinic cholinergic receptors

- with ^{123}I -Iododexetimide in rat brain and heart. In: Schmidt HAE, Höfer R, eds. Nuclear Medicine in Research and Practice. European Nuclear Medicine Congress, Vienna, September 1-5, 1991. Schattauer Stuttgart-New York. Nucl Med 1992; Suppl 28: 212-215.
13. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Stam J, Roolker L, Wiggerts HO, Beer HF. Dynamic studies of the binding of ^{123}I -Iomazenil to central benzodiazepine receptors in healthy volunteers. In: Schmidt HAE, Höfer R, eds. Nuclear Medicine in Research and Practice. European Nuclear Medicine Congress, Vienna, September 1-5, 1991. Schattauer Stuttgart-New York. Nucl Med 1992; Suppl 28: 175-178.
 14. **Verhoeff NPLG**, Van Royen EA, Linszen DH, Janssen AGM, Huyser C, Van den Brande J. In vivo dopamine D2-receptor imaging with I-123 Iodobenzamide SPECT using a long-bore collimator. In: Schmidt HAE, Höfer R, eds. Nuclear Medicine in Research and Practice. European Nuclear Medicine Congress, Vienna, September 1-5, 1991. Schattauer Stuttgart-New York. Nucl Med 1992; Suppl 28: 422-425.
 15. **Verhoeff NPLG**, Van Royen EA, Overweg J, Gutter T, Beer HF. Central benzodiazepine receptor imaging with ^{123}I -Iomazenil SPECT combined with EEG in patients with partial epilepsy. In: Schmidt HAE, Höfer R, eds. Nuclear Medicine in Research and Practice. European Nuclear Medicine Congress, Vienna, September 1-5, 1991. Schattauer Stuttgart-New York. Nucl Med 1992; Suppl 28: 179-182.
 16. **Verhoeff NPLG**, Costa DC, Ell PJ, Toone B, Palasidou E, Cullum ID, Bobeldijk M, Miller R, Syed GMS, Barrett JJ, Soricelli A, Van Royen EA. Dopamine D2-receptor imaging with dynamic I-123 IBZM SPET in patients with schizophrenia or HIV encephalopathy. In: Schmidt HAE, Van der Schoot JB, eds. The State of the Art of Nuclear Medicine in Europe. European Nuclear Medicine Congress, Amsterdam, May 20-24, 1990. Schattauer Stuttgart-New York. Nucl Med 1991; Suppl 17: 207-212.
 17. **Verhoeff NPLG**, Van Royen EA, Ell PJ, Costa DC, Hasler PH, Schubiger PA. Benzodiazepine receptor density in human brain measured in vivo with ^{123}I -Iomazenil SPECT. In: Schmidt HAE, Van der Schoot JB, eds. The State of the Art of Nuclear Medicine in Europe. European Nuclear Medicine Congress, Amsterdam, May 20-24, 1990. Schattauer Stuttgart-New York. Nucl Med 1991; Suppl 27: 203-206.
 18. **Verhoeff NPLG**, Van Kanten J, Van der Zant FM, Van Royen EA, Weinstein H, Limburg M. A comparison of Tl-201-DDC and Tc-99m-HMPAO SPECT in patients with ischemic stroke or dementia. In: Schmidt HAE, Van der Schoot JB, eds. The State of the Art of Nuclear Medicine in Europe. European Nuclear Medicine Congress, Amsterdam, May 20-24, 1990. Schattauer Stuttgart-New York. Nucl Med 1991; Suppl 27: 231-236.
 19. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Hijdra A, Linszen D. Benzodiazepine receptor density in human cerebral cortex and cerebellum measured in vivo with ^{123}I -Iomazenil SPECT. In: Schubiger PA, Hasler PH, eds. Iomazenil and Other Brain Receptor Tracers for SPECT. Proceedings of the 6th Böttstein Colloquium. Würenlingen/Villigen, Switzerland, November 10 and 11, 1989. Editiones <Roche>, Basel, Switzerland 1990: 77-82.

Book chapters, co-author:

1. Tauscher J, **Verhoeff NPLG**. Serotonergic dysfunctions in schizophrenia. In: Soares JC, Gershon S, eds. Handbook of Medical Psychiatry. Marcel Dekker, Inc., New York, NY, USA 2003: 267-275.

2. Tikofsky RS, Ichise M, Seibyl JP, **Verhoeff NPLG**. Functional Brain SPECT Imaging: 1999 and Beyond. In: LM Freeman, ed. Nuclear Medicine Annual 1999; Lippincott Williams & Wilkins, New York, NY, USA 1999: 193-263.
3. Lucey JV, Pilowsky LS, Costa DC, Ell PJ, **Verhoeff NPLG**, Kerwin RW. ^{123}I -IBZM SPECT Brain Imaging In Schizophrenia. In: Grünwald F, Kasper S, Biersack HJ, Möller HJ, eds. Brain SPECT Imaging in Psychiatry. Walter de Gruyter, New York, NY, USA 1995: 175-192.
4. Aldenkamp AP, Vermeulen J, Alpherts WCJ, Overweg J, **Verhoeff NPLG**. Validity of computerized testing: patient dysfunction and complaints versus measured changes. In: Dodson WE, Kinsbourne M, eds. Validity of computerized assessment. Demos, New York, NY, USA 1992: 51-68.
5. Ring HA, Trimble MR, Costa DC, Ell PJ, George MS, **Verhoeff NPLG**. Effect of vigabatrin on striatal dopamine receptors. In: Schmidt HAE, Höfer R, eds. Nuclear Medicine in Research and Practice. European Nuclear Medicine Congress, Vienna, September 1-5, 1991. Schattauer Stuttgart-New York. Nucl Med 1992; Suppl 28: 418-421.

Abstracts, letters, posters and other publications, first author:

1. **Verhoeff NPLG**. Effects of catecholamine depletion on D_2 receptor binding and mood in healthy humans. Int J Neuropsychopharmacology 2006; 9 (Suppl 1): S58.
2. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, St. George-Hyslop P, Hussey D, Takeshita S, Trop L, Singh K, Kung HF, Kung MP, Houle S. [^{11}C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Neurobiology of Aging 2004; 25 (S2): S58-S59 (Abstract).
3. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, St. George-Hyslop P, Hussey D, Takeshita S, Trop L, Singh K, Kung HF, Kung MP, Houle S. [^{11}C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Alzheimer's Imaging Consortium. An Official satellite of The 9th International Conference on Alzheimer's Disease and Related Disorders in Philadelphia, Pennsylvania, USA, July 17-22, 2004: 44-45 (Abstract).
4. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, St. George-Hyslop P, Hussey D, Trop L, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [^{11}C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Molecular Imaging and Biology 2004; 6: 76 (Abstract).
5. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [^{11}C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? International College of Geriatric Psychoneuropharmacology 3rd Annual Meeting, San Juan, Puerto Rico, December 12-14, 2003: 66 (Abstract).
6. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Houle S. Development of positron emission tomography (PET) tracers for beta-amyloid imaging in vivo. J Cereb Blood Flow Metab 2003; 23 (Suppl 1): 685 (Abstract).
7. **Verhoeff NPLG**, Christensen BK, Bagby RM, Hussey D, Lee M, Papatheodorou G, Kopala L, Rui Q, Zipursky RB, Kapur S. Effects of catecholamine depletion on D_2 receptor binding, mood, attentiveness and personality in humans. NeuroImage 2002; 16: S51 (Abstract).
8. **Verhoeff NPLG**, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S. Dopamine depletion results in increased neostriatal

- D₂, but not D₁, receptor binding in humans. American College of Neuropsychopharmacology 40th Annual Meeting, Waikoloa, Hawaii, December 9-13, 2001: 217 (Abstract).
9. **Verhoeff NPLG**, Kapur S, Hussey D, Lee M, Christensen B, Papatheodorou G, Zipursky RB. Baseline neostriatal dopamine levels in healthy subjects. American College of Neuropsychopharmacology 39th Annual Meeting, San Juan, Puerto Rico, December 10-14, 2000: 137 (Abstract).
 10. **Verhoeff NPLG**, Meyer JH, Kecojevic A, Hussey D, Lewis R, Kapur S. A voxel-by-voxel analysis of [¹⁸F]setoperone PET serotonin_{2A} receptor data in schizophrenia. Biol Psychiatry 2000; 47: 48S-49S (Abstract).
 11. **Verhoeff NPLG**, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, Baldwin RM, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, van Dyck CH, Krystal JH, Innis RB. Nicotine use effects on brain benzodiazepine receptors in schizophrenia measured by [¹²³I]iomazenil SPECT. College on Problems of Drug Dependence 1999 61st Annual Meeting, Acapulco, Mexico, June 12-17, 1999: 166 (Abstract).
 12. **Verhoeff NPLG**, Petroff OAC, Hyder F, Zoghbi SS, Baldwin RM, Fujita M, Rajeevan N, Seibyl JP, Mattson R, Innis RB. Effects of vigabatrin on the GABA-ergic system as determined by [I-123]iomazenil SPECT. J Nucl Med 1998; 39: 26P (Abstract).
 13. **Verhoeff NPLG**, Soares JC, D'Souza CD, Gil R, Degen K, Wexler B, Abi-Dargham A, Baldwin RM, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, Innis RB. Benzodiazepine receptor imaging using [I-123]iomazenil SPECT in schizophrenia. J Nucl Med 1998; 39: 82P (Abstract).
 14. **Verhoeff NPLG**, Soares JC, D'Souza CD, Gil R, Degen K, Wexler B, Abi-Dargham A, Innis RB. Benzodiazepine receptor SPECT in schizophrenia. American Psychiatric Association 151st Annual Meeting May 30-June 4, 1998, Toronto, Ontario, Canada. New Research Program & Abstracts. American Psychiatric Association, Washington, DC, USA 1998: 116 (Abstract).
 15. **Verhoeff NPLG**. Benzodiazepine receptor binding and schizophrenia. Am J Psychiatry 1997; 154: 1480 (Letter).
 16. **Verhoeff NPLG**. SPECT of the dopaminergic system in Parkinsonian syndromes. Acta Neurol Belg 1995; 95 (Suppl): 50-51 (Abstract).
 17. **Verhoeff NPLG**, Meylaerts SAG, Miedema AR, Van Royen EA, Assies J, Van der Zant FM. Somatostatin receptor imaging in the pituitary using [In-111 DTPA]-octreotide and high resolution brain SPECT. J Nucl Med 1993; 34: 41P-42P (Abstract).
 18. **Verhoeff NPLG**, Speelman JD, Kuiper MA, Van Royen EA, Kapucu O, Boer GJ, Janssen AGM, Wolters ECh. Dopamine D2 receptor imaging with I-123 iodomezamide SPECT in patients with the Parkinsonian syndrome: clinical significance. J Nucl Med 1993; 34: 207P (Abstract).
 19. **Verhoeff NPLG**. Afbeelding van het dopaminerge systeem in vivo bij het Parkinsonsyndroom. Nucl Geneesk Bull 1993; 15: 111 (Abstract).
 20. **Verhoeff NPLG**, Kapucu O, Sokole-Busemann E, Van Royen EA, Janssen AGM. Quantification of dopamine D2 receptor binding potential in the striatum with I-123 IBZM SPECT: technical and inter-observer variability. J Nucl Med 1993; 34: 209P (Abstract).
 21. **Verhoeff NPLG**, Assies J, Janssen AGM, Van Royen EA. Dopamine D2-receptor SPECT with ¹²³I-iodobenzamide in a patient with malignant

- macroprolactinoma. Eur J Nucl Med 1992; 19: 682 (Abstract).
22. **Verhoeff NPLG**, Kuiper MA, Speelman JD, Kapucu O, van Royen EA, Janssen AGM, Wolters ECh. Dopamine D₂ receptor imaging with ¹²³I-IBZM SPECT in patients with parkinsonism. Mov Disord 1992; 7 (Suppl. 1): 148 (Abstract).
 23. **Verhoeff NPLG**, Sokole-Busemann E, Kapucu O, Erbas B, Van Royen EA, Van der Weel FA, Janssen AGM. Fantoomstudies voor semikwantificering van hersensPECT. Ned Tijdschr Geneesk 1992; 136: 1884 (Abstract).
 24. **Verhoeff NPLG**, Speelman JD, Kuiper MA, Kapucu O, Van Royen EA, Janssen AGM, Wolters EChMJ. Dopamine D₂-receptor imaging with ¹²³I-IBZM SPECT for the differential diagnosis of Parkinsonism. Nucl Med Commun 1992; 13: 237 (Abstract).
 25. **Verhoeff NPLG**, Speelman JD, Kuiper MA, Kapucu O, Van Royen EA, Janssen AGM, Wolters ECh. Dopamine D₂-receptor imaging with I-123 IBZM SPECT in patients with Parkinson's disease with and without dopaminergic medication. J Nucl Med 1992; 33: 917 (Abstract).
 26. **Verhoeff NPLG**, Speelman JD, Kuiper MA, Kapucu O, Van Royen EA, Janssen AGM, Wolters EChMJ. Dopamine D₂-receptor imaging with I-123 IBZM SPECT in patients with unilateral Parkinson's disease. J Nucl Med 1992; 33: 1016-1017 (Abstract).
 27. **Verhoeff NPLG**, Vermeulen RJ, Wiersma H, De Bruin K, Janssen AGM, Van Royen EA. Long-term upregulation of dopamine D₂-receptors in a MPTP primate model demonstrated with ¹²³I-IBZM SPECT. Eur J Nucl Med 1992; 19: 730 (Abstract).
 28. **Verhoeff NPLG**, Van Royen EA, Speelman JD, Borm JJJ, Kapucu O. Differential diagnosis of Parkinsonism by I-123 IBZM SPECT. J Nucl Med 1992; 33: 917 (Abstract).
 29. **Verhoeff NPLG**, Van Royen EA, Speelman JD, Wolters EC, Kuiper MA. Parkinsonisme, een eenvoudige diagnose? Ned Tijdschr Geneesk 1992; 136: 757 (Letter).
 30. **Verhoeff NPLG**. Celbiologie vanuit een medisch perspectief. X. Signaaltransductie. Ned Tijdschr Geneesk 1992; 136: 802 (Letter).
 31. **Verhoeff NPLG**, Erbas B, Kapucu O, Stam J, Blok H, Van Royen EA. Central benzodiazepine receptor imaging with dynamic ¹²³I-iomazenil SPET in healthy volunteers. Eur J Nucl Med 1992; 19: 737 (Abstract).
 32. **Verhoeff NPLG**. Halfwaardetijd van haloperidol in plasma versus in the hersenen gemeten met SPECT of PET. Ned Tijdschr Geneesk 1992; 136: 543 (Letter).
 33. **Verhoeff NPLG**, Van Breukel A, Maas MAW, Van Royen EA. In vivo binding of muscarinic cholinergic receptors with I-123 Iododexetimide in rat brain. Eur J Nucl Med 1991; 18: 569 (Abstract).
 34. **Verhoeff NPLG**, Van Royen EA, Horn J, Spilt A, Koolbergen DK, Mol BW, Bobeldijk M. Whole body distribution of I-123 Iodobenzamide in 6 healthy human volunteers. J Nucl Med 1991; 32: 1018 (Abstract).
 35. **Verhoeff NPLG**, Van Royen EA, Linszen DH, Huyser C, Bobeldijk M. In vivo dopamine D₂-receptor imaging with I-123 Iodobenzamide SPECT using a long-bore collimator. Eur J Nucl med 1991; 18: 564 (Abstract).
 36. **Verhoeff NPLG**, Van Royen EA, Overweg J, Beer HF. Central benzodiazepine

- receptor density measured with I-123 Iomazenil in healthy volunteers and in patients with partial epilepsy under continuous EEG monitoring. Eur J Nucl Med 1991; 18: 616 (Abstract).
37. **Verhoeff NPLG**, Van Royen EA, Linszen DH, Huyser C, Bobeldijk M. Iodium-123-IBZM SPECT met de long-bore collimator of oude SPECT in de schoot van een nieuwe toekomst. Nucl Geneesk Bull 1991; 13: 73-75 (Abstract).
 38. **Verhoeff NPLG**, Bobeldijk M, Boer GJ, Feenstra MGP, Erdtsieck-Ernste E, Van Royen EA. In vitro binding of muscarinic cholinergic receptors with I-123 Iododexetimide in rat brain. J Nucl Med 1991; 32: 1097 (Abstract).
 39. **Verhoeff NPLG**, Bobeldijk M, Boer GJ, Feenstra MGP, Erdtsieck-Ernste E, Van Royen EA. In vitro binding of muscarinic cholinergic receptors with I-123 Iododexetimide in rat brain. Eur J Nucl Med 1991; 18: 641 (Abstract).
 40. **Verhoeff NPLG**, Boer GJ, Feenstra MGP, Van Royen EA. In vitro binding of muscarinic cholinergic receptors with ¹²³I-Iododexetimide in rat brain. Proceedings of the 32nd Dutch Federation Meeting of the Federation of Medical Scientific Societies Amsterdam 3-4 April 1991: 194 (Abstract).
 41. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M. A kinetic analysis of the binding of I-123 Iomazenil to central benzodiazepine receptors in healthy volunteers. Eur J Nucl med 1991; 18: 537 (Abstract).
 42. **Verhoeff NPLG**, Van Royen EA, Van Royen N, Van Breemen B, Van den Hazel SJ, Bol I, Vernulst A, Bobeldijk M. Dopamine D2-receptor imaging with dynamic ¹²³I iodobenzamide SPECT in six healthy human volunteers. Nucl Med Commun 1991; 12: 294 (Abstract).
 43. **Verhoeff NPLG**, Van Royen EA, Van Royen N, Van Breemen B, Van den Hazel SJ, Bol I, Verhulst A, Bobeldijk M. Dopamine D2-receptor imaging with dynamic I-123 Iodobenzamide SPECT in 6 healthy human volunteers. J Nucl Med 1991; 32: 1078 (Abstract).
 44. **Verhoeff NPLG**, Van Vlies B, Maas MAW, De Bruin K, Olivier G, Van Royen EA. In vivo binding of muscarinic cholinergic receptors with I-123 Iododexetimide in rat heart. Eur J Nucl Med 1991; 18: 568 (Abstract).
 45. **Verhoeff NPLG**, Bobeldijk M, Van Royen EA, Boer GJ, Feenstra MGP, Erdtsieck-Ernste E. In Vitro Binding of Dopamine D2-receptors with ¹²³[I] Iodobenzamide in Human Brain. Proceedings of the 31st Dutch Federation Meeting of the Federation of Medical Scientific Societies Leiden 18-19 April 1990: 229 (Abstract).
 46. **Verhoeff NPLG**, Bobeldijk M, Van Royen EA, Feenstra MGP, Boer GJ, Van Doremalen PAMP, Erdtsieck-Ernste E. In vitro and in vivo binding of dopamine D2-receptors with ¹²³I iodobenzamide in rat and human brain. Eur J Pharmacol 1990; 183: 1414 (Abstract).
 47. **Verhoeff NPLG**, Costa DC, Ell PJ, Toone B, Palasidou E, Cullum ID, Bobeldijk M, Syed GMS, Van Royen EA. Assessment of dopamine D2-receptor density and occupancy in patients with schizophrenia with and without neuroleptics using I-123 IBZM SPET. Eur J Nucl Med 1990; 16: 561 (Abstract).
 48. **Verhoeff NPLG**, Van Kanten J, Van Royen EA, De Bruïne JF, Limburg M. A comparison of Tl-201 DDC and Tc-99m HMPAO SPECT and CT in patients with a cerebrovascular accident. Eur J Nucl Med 1990; 16: 559 (Abstract).
 49. **Verhoeff NPLG**, Speelman JD, Van Royen EA, De Jong JMBV. In vivo dopamine D2-receptor imaging with I-123 iodobenzamide SPECT in patients with

- multiple system atrophy. Eur J Nucl Med 1990; 16: 520 (Abstract).
50. **Verhoeff NPLG**, Van Kanten J, Van Royen EA, De Bruïne JF, Limburg M. A comparison of Tl-201 DDC and Tc-99m HMPAO SPECT and CT in patients with a cerebrovascular accident. Nucl Geneeskd Bull 1990; 12: P 58 (Poster).
 51. **Verhoeff NPLG**, Van Kanten J, Van Royen EA, Weinstein HC, Van der Zant FM. A comparison of Tl-201 DDC and Tc-99m HMPAO SPECT in patients with dementia. Eur J Nucl Med 1990; 16: 522 (Abstract).
 52. **Verhoeff NPLG**, Van Kanten J, Van Royen EA, Weinstein HC, Van der Zant FM. A comparison of Tl-201 DDC and Tc-99m HMPAO SPECT in patients with dementia. Nucl Geneeskd Bull 1990; 12: P 55 (Poster).
 53. **Verhoeff NPLG**, Van Royen EA, Costa DC, Cullum ID, Lui D, Ell PJ, Syed GMS, Barrett JJ, Toone B. A Study of the Dopamine D2 Receptor in Human Brain with ¹²³I-IBZM SPET. Nucl Med Commun 1990; 3: 246 (Abstract).
 54. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Hijdra A, Linszen D. ¹²³I Iomazenil whole body distribution in human volunteers. Eur J Nucl Med 1990; 16: 461 (Abstract).
 55. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Hijdra A, Linszen D. ¹²³I Iomazenil whole body distribution in human volunteers. Nucl Geneeskd Bull 1990; 12: P 46 (Poster).
 56. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Hijdra A, Linszen D. ¹²³I Iomazenil dynamic whole brain activity in human volunteers. Eur J Nucl Med 1990; 16: 520 (Abstract).
 57. **Verhoeff NPLG**, Van Royen EA, Overweg J, Limburg M, Hijdra A, Linszen D. Benzodiazepine receptor density in human brain measured in vivo with ¹²³I Iomazenil SPECT. Eur J Nucl Med 1990; 16: 408 (Abstract).
 58. **Verhoeff NPLG**, Costa DC, Miller R, Ell PJ, Cullum ID, Bobeldijk M, Wijnhoven G, Van Royen EA. Assessment of dopamine D2-receptor density in patients with AIDS using I-123 IBZM SPET. Eur J Nucl Med 1990; 16: 561 (Abstract).
 59. **Verhoeff NPLG**, Bobeldijk M, Van Royen EA, Feenstra MGP, Boer GJ, Van Doremalen PAMP. In vitro and in vivo binding of dopamine D2-receptors with ¹²³I-Iodobenzamide in rat brain. Pharmaceutisch Weekblad Scientific edition 1989; 11 Suppl J: J13 (Abstract).

Abstracts, letters, posters and other publications, co-author:

1. Chow T, Rusjan P, Meyer J, **Verhoeff NPLG**, Pollock BG, Smith G. Frontal-subcortical circuits and a rationale for neuroreceptor quantification in frontotemporal dementia. Neuropsychopharmacology 2006;31(Supp 1):S48.
2. Chow TW, **Verhoeff NPLG**, Takeshita S, St. Jacques PL, Freedman M, Black S, Wilson A, Hussey D, Houle S, Meyer J. Reduced serotonin 1a receptor binding potential and abnormal oral behaviors in frontotemporal degeneration. Neurology 2005; 64 (Abstract in publication).
3. Chow TW, **Verhoeff NPLG**, Takeshita S, St. Jacques PL, Freedman M, Black S, Wilson A, Hussey D, Houle S, Meyer J. Depression in frontotemporal dementia is associated with decreased left temporal lobe 5HT1a receptor

density. *Annals of Neurology* 2004; 56(S8): S17 (Abstract).

4. Staley JK, Petrakis I, Gottschalk C, Seibyl JP, **Verhoeff NPLG**, Perry E, Van Dyck C, Baldwin RM, Krystal JH. Benzodiazepine receptor availability in recently abstinent alcohol dependent males: relationship to craving, withdrawal and smoking. American College of Neuropsychopharmacology 42nd Annual Meeting, San Juan, Puerto Rico, December 8-12, 2003: 69 (Abstract).
5. Lanctôt KL, Hussey D, Herrmann N, Black SE, Khan LR, **Verhoeff NPLG**, Houle S, Kapur S. Comparison of serotonin 5-HT_{1A} receptor binding potential in Alzheimer's disease (AD) versus controls using [¹¹C]WAY-100635 and PET [abstract]. Presented at the 128th Annual Meeting of the American Neurological Association, San Francisco, CA, October 19-22, 2003. *Annals of Neurology* 2003; 54(S7): S29 (Abstract).
6. Lanctôt KL, Herrmann N, Hussey D, Khan LR, Black SE, **Verhoeff NPLG**, Houle S, Kapur S. Serotonin 5-HT_{1A} receptor binding potential in frontotemporal dementia (FTD) compared to controls using [¹¹C]WAY-100635 and PET [abstract]. Presented at the 128th Annual Meeting of the American Neurological Association, San Francisco, CA, October 19-22, 2003. *Annals of Neurology* 2003; 54(S7): S67 (Abstract).
7. Staley JK, Petrakis I, Gottschalk PC, Zoghbi S, **Verhoeff NPLG**, Seibyl JP, Van Dyck C, Innis RB, Baldwin RM, Krystal JH. [¹²³I]iomazenil SPECT imaging of acutely detoxified alcoholics during early recovery. *Society for Neuroscience Abstracts* 2002; Program No. 899.12 (Abstract).
8. Staley JK, Mason G, Petrakis I, Zoghbi SS, **Verhoeff NPLG**, Seibyl JP, Van Dyck CH, Innis RB, Baldwin RM, Krystal JH. Assessment of cortical GABA function in acutely (< 7 days) detoxified alcohol dependent patients. *J Nucl Med* 2002; 43: 109P (Abstract).
9. Kugaya A, Sanacora G, **Verhoeff NPLG**, Fujita M, Seneca NM, Khan SA, Anand A, Degen K, Mason GF, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB. In vivo cortical benzodiazepine receptor binding and GABA levels in patients with unipolar major depression. *J Nucl Med* 2001; 42: 17P (Abstract).
10. Hussey D, Meyer JH, Kapur S, **Verhoeff NPLG**, Tauscher J, Cheung K, Houle S. Sensitivity of Voxel Based Comparisons for PET ligands with SPM. *Neuroimage* 2001; 13: S158 (Abstract).
11. Tauscher J, Kapur S, **Verhoeff NLPG**, Daskalakis ZJ, Tauscher-Wisniewski S, Papatheodorou G, Zipursky RB. PET imaging of 5-HT_{1A} receptors in schizophrenia. *Schizophr Res* 2001; 49 (Suppl. 1-2): 196 (Abstract).
12. Tauscher J, **Verhoeff NPLG**, Hussey D, Meyer JH, Kecojevic A, Kasper S, Kapur S. Age-related decline of 5HT-1A receptor binding. American Psychiatric Association 153rd Annual Meeting May 12-19, 2000, Chicago, Illinois, USA. New Research Program & Abstracts. American Psychiatric Association, Washington, DC, USA 2000: 85 (Abstract).

13. Anand A, **Verhoeff NPLG**, Charney DS, Seibyl JP, Innis RB. SPECT of the dopaminergic system in bipolar disorder. J Nucl Med 1999; 40: 144P (Abstract).
14. Fujita M, **Verhoeff NPLG**, Varrone A, Zoghbi SS, Baldwin RM, Rajeevan N, Seibyl JP, Charney DS, Innis RB. Imaging of extrastriatal D₂ receptor occupancy by endogenous dopamine in humans. J Nucl Med 1999; 40: 31P (Abstract).
15. Ichise M, Fujita M, Seibyl JP, **Verhoeff NPLG**, Baldwin RM, Zoghbi SS, Rajeevan N, Charney DS, Innis RB. Multilinear regression graphical and simplified analyses of striatal and extrastriatal dopamine D₂ receptor binding with [¹²³I]epidepride SPECT. J Nucl Med 1999; 40: 36P (Abstract).
16. Varrone A, Fujita M, **Verhoeff NPLG**, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB. Test-retest reproducibility of extrastriatal dopamine D₂ receptor imaging with [I-123]epidepride SPECT in humans. J Nucl Med 1999; 40: 67P (Abstract).
17. Fujita M, Seibyl J, **Verhoeff NPLG**, Baldwin R, Zoghbi S, Burger C, Ichise M, Staley J, Rajeevan N, Charney D, Innis R. Comparison of methods for quantitative measurement of striatal and extrastriatal dopamine D₂ receptors with [I-123]epidepride. J Nucl Med 1998; 39: 123P (Abstract).
18. Fujita M, **Verhoeff NPLG**, Baldwin RM, Zoghbi SS, Rajeevan N, Seibyl JP, Innis RB. Reproducibility of [I-123]iomazenil equilibrium measurement of benzodiazepine receptors. J Nucl Med 1998; 39: 208P (Abstract).
19. Fujita M, Woods SW, **Verhoeff NPLG**, Abi-Dargham A, Soares JC, Jatlow PA, Baldwin RM, Zoghbi SS, Seibyl JP, Rajeevan N, Krystal JH, Innis RB. Changes of benzodiazepine receptor and development of tolerance during chronic benzodiazepine administration in healthy human subjects. J Nucl Med 1998; 5: 13P (Abstract).
20. Ichise M, Fujita M, Seibyl JP, **Verhoeff NPLG**, Baldwin RM, Zoghbi SS, Rajeevan N, Charney DS, Innis RB. Graphical modeling of dopamine D₂ receptor binding of I-123-epidepride to account for labeled lipophilic metabolites. J Nucl Med 1998; 39: 72P (Abstract).
21. Fujita M, Seibyl JP, Baldwin RM, Zoghbi SS, Burger C, **Verhoeff NPLG**, Rajeevan N, Charney DS, Innis RB. In vivo quantification of extrastriatal dopamine D_{2/3} receptors with [I-123]epidepride SPECT imaging. Society for Neuroscience Abstracts 1997; 23: 1774 (Abstract).
22. Fujita M, Al-Tikriti MS, Seibyl JP, Baldwin, RM, Zoghbi SS, Burger C, **Verhoeff NPLG**, Rajeevan N, Charney DS, Innis RB. Imaging with dopamine D_{2/3} receptors with [I-123]epidepride - kinetic and equilibrium studies. J Nucl Med 1997; 38: 81P (Abstract).
23. Lawrie SM, Ebmeier KP, **Verhoeff NPLG**, van Royen EA, Johnstone EC, Goodwin GM. Benzodiazepine GABA-A receptor binding in schizophrenia - a study with single photon emission tomography and ¹²³I-iomazenil. VIIIth Biennial Winter Workshop on Schizophrenia. Schizophrenia Res 1996; 18:

- 199 (Abstract).
24. Potenza M, **Verhoeff NPLG**, Weiss E. Comic books and development. *J Am Acad Child Adolesc Psychiatry* 1996; 35: 1573-1574 (Letter).
 25. Busatto GF, Pilowsky LS, Ell PJ, Costa DC, **Verhoeff NPLG**, Kerwin RW. Dopamine D₂ receptor occupancy in vivo and response to the new antipsychotic risperidone. *Br J Psychiatry* 1993; 163: 833-834 (Letter).
 26. Van der Zant FM, **Verhoeff NPLG**, Rehmann CJ, Tiel-van Buul MMC, Van Royen EA. Clinical experience with OctreoScan. *Nucl Med Commun* 1993; 14: 234 (Abstract).
 27. Vermeulen RJ, Drukarch B, Witter MP, **Verhoeff NPLG**, van Royen EA, Wolters ECh, Goossen C, Stoof JC. Correlation between dopamine D₂ receptor induced behavior and in vivo receptor occupancy in a monkey model of Parkinson's disease. *Society for Neuroscience Abstracts* 1993; 19: 1051 (Abstract).
 28. Van Dongen A, **Verhoeff NPLG**, Bemelman F, Van Royen EA. Somatostatin receptor imaging with ¹¹¹In-pentatreotide for whole body studies and high resolution brain SPECT. *Eur J Nucl Med* 1992; 19: 679 (Abstract).
 29. Van Royen EA, **Verhoeff NPLG**, Speelman JD. Verminderde dopamine D₂-activiteit bij multipole systeematrofie. *Nucl Geneeskd Bull* 1992; 14: 29 (Abstract).
 30. Vermeulen RJ, **Verhoeff NPLG**, Van Royen EA, Wolters E Ch, Goosen C, Stoof JC. Evaluation of dopamine D-2 receptor binding in vivo with SPECT using [¹²³I]IBZM in unilaterally MPTP-lesioned monkeys. *Abstracts of the 7th International catecholamine Symposium. Free University Amsterdam, June 22-26, 1992: 339 (Abstract).*
 31. Bokkinga A, Cheung Tam He MAKK, **Verhoeff NPLG**, Busemann-Sokole E, Janssen AGM, Van Royen EA. Fantoomstudies ter validering van dynamische SPECT. *Nucl Geneeskd Bull* 1992; 14: 29-30 (Abstract).
 32. Costa DC, George MS, Ell PJ, **Verhoeff NPLG**, Robertson MM. D₂ Dopamine receptor studies in patients with Gilles de la Tourette syndrome. *Eur J Nucl Med* 1991; 18: 563 (Abstract).
 33. Ring HA, Trimble MR, Costa DC, **Verhoeff NPLG**, Ell PJ. Effects of vigabatrin on striatal dopamine receptors. *Eur J Nucl Med* 1991; 18: 563 (Abstract).
 34. Overweg J, **Verhoeff NPLG**, Van Royen EA, Aldenkamp AP, Verbeeten BWJM, Weinstein HC. Memory disorders and focus localisation with Tc-99m HMPAO SPECT, EEG and CT in patients with partial epilepsy. *Eur J Nucl Med* 1990; 16: 522 (Abstract).
 35. Overweg J, **Verhoeff NPLG**, Van Royen EA, Aldenkamp AP, Verbeeten BWJM, Weinstein HC. Memory disorders and focus localisation with Tc-99m HMPAO SPECT, EEG and CT in patients with partial epilepsy. *Nucl Geneeskd Bull* 1990; 12: P 59 (Poster).
 36. Weinstein HC, Jonker C, Van Royen EA, Hijdra A, Derix MM, **Verhoeff NPLG**, Walstra G. SPECT in early and late onset Alzheimer's disease. *Eur J Nucl Med* 1990; 16: 455 (Abstract).
 37. Speelberg B, **Verhoeff NPLG**, Van den Berg NJ, Oosthoek CHA, Van den Brink WTJ. Does nedocromil sodium protect against the late asthmatic reaction after exercise? *Am Rev Respir Dis* 1989; 4: A 88 (Abstract).

Oral Conference Presentations (besides published abstracts mentioned above):

1. **Verhoeff NPLG.** Alcohol and substance abuse in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, October 30th, 2006.
2. **Verhoeff NPLG.** Agitation and psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, October 30th, 2006.
3. **Verhoeff NPLG.** Behavioural problems in dementia: epidemiology and clinical course. Presentation at the joint Conference by Kunin-Lunenfeld Applied Research Unit - Baycrest, the Centre for Addiction and Mental Health Geriatric Mental Health Program, and the University of Toronto Division of Geriatric Psychiatry: "Behavioural Problems in Dementia - - Late-Life Depression: Connecting Research & Clinical Care". University of Toronto, 89 Chestnut Street, Toronto, October 20th, 2006.
4. **Verhoeff NPLG.** Effects of catecholamine depletion on D₂ receptor binding and mood in healthy humans. Presentation at the 25th Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP), Chicago, Illinois, USA, July 12th, 2006.
5. Honjo K, **Verhoeff NPLG.** Alzheimer's disease and cerebrovascular disease - links with amyloid beta protein. Presentation at the Kunin-Lunenfeld Applied Research Unit Rounds. Toronto, ON, Canada, June 14th, 2006.
6. **Verhoeff NPLG**, Honjo K. What relevant aspects of the •-amyloid cascade do we image with [¹¹C]SB-13 PET? Presentation at the Neuroscience Rounds at at Sunnybrook and Women's College Health Sciences Centre. Toronto, ON, Canada, June 1st, 2006.
7. **Verhoeff NPLG.** Nuclear medicine: how can it help to optimize treatment for schizophrenia? Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, May 12th, 2006.
8. **Verhoeff NPLG.** Alcohol and substance abuse in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, April 3rd, 2006.
9. **Verhoeff NPLG.** Agitation and psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, February 27th, 2006.
10. **Verhoeff NPLG.** Acetylcholine and amyloid: connections between cholinergic neurotransmission and the β -amyloid cascade. Presentation at the PET Centre Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, February 24th, 2006.
11. **Verhoeff NPLG.** Nuclear medicine: how can it help to optimize treatment for schizophrenia? Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, February 1st, 2006.
12. Honjo K, **Verhoeff NPLG.** Alzheimer's disease and cerebrovascular disease - links with amyloid beta protein. Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, January 25th, 2006.

13. Honjo K, **Verhoeff NPLG**. Alzheimer disease (AD) and cerebrovascular disease (CVD) - links with amyloid beta (A β) protein. Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, January 20th, 2006.
14. Van Reekum R, **Verhoeff NPLG**. Traumatic brain injury and Alzheimer's disease. Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, December 16th, 2005.
15. Rapoport M, Van Reekum R, **Verhoeff NPLG**. Traumatic brain injury and Alzheimer's disease. Presentation at the Rotman Research Institute Rounds. Toronto, ON, Canada, December 5th, 2005.
16. Honjo K, **Verhoeff NPLG**. What relevant aspects of the β -amyloid cascade do we image with [¹¹C]SB-13 PET? Presentation at the PET Centre Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, November 18th, 2005.
17. **Verhoeff NPLG**. Alcohol and substance abuse in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, October 31st, 2005.
18. **Verhoeff NPLG**. Nuclear medicine: how can it help to optimize treatment for schizophrenia? Presentation at the Annual Scientific Congress of the European Association of Nuclear Medicine, Istanbul, Turkey, October 16th, 2005.
19. **Verhoeff NPLG**. Dopamine and psychomotor retardation in depression. Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, September 30th, 2005.
20. **Verhoeff NPLG**. Agitation and psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, August 22nd, 2005.
21. **Verhoeff NPLG**. Neurological Examination for Psychiatrists. Presentation at Geriatric Psychiatry Residents' Seminar Day, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, August 9th, 2005.
22. **Verhoeff NPLG**. In vivo imaging of Alzheimer's disease β -amyloid with [¹¹C]SB-13 PET. Presentation at the 31st Annual Harvey Stancer Research Day. Toronto, ON, Canada, June 16th, 2005.
23. **Verhoeff NPLG**. Formulation Seminar for Geriatric Psychiatry Residents. Baycrest Centre for Geriatric Care. Toronto, ON, Canada, June 2nd, 2005.
24. **Verhoeff NPLG**. Acetylcholine and amyloid: connections between cholinergic neurotransmission and the β -amyloid cascade. Presentation at the Neuroscience Rounds at Sunnybrook and Women's College Health Sciences Centre. Toronto, ON, Canada, May 5th, 2005.
25. **Verhoeff NPLG**. Cortical GABA_A/Benzodiazepine Receptors in Recovery from Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking. Presentation at that Addiction Psychiatry Rounds at the Centre for Addiction and Mental Health. Toronto, ON, Canada, April 22nd, 2005.
26. **Verhoeff NPLG**. Is there evidence from prospective cohort studies that apolipoprotein E epsilon 4 allele status affects the likelihood that

traumatic brain injury will be followed by Alzheimer's disease?
 Presentation at Evidence Based Clinical Practice Seminars, Baycrest
 Centre for Geriatric Care. Toronto, ON, Canada, April 11th, 2005.

27. **Verhoeff NPLG.** Patient with prominent cognitive and mood symptoms.
 Presentation at Rounds at the Department of Behavioural Neurology,
 Baycrest Centre for Geriatric Care. Toronto, ON, Canada, April 6th, 2005.
28. **Verhoeff NPLG.** Cortical GABA_A/Benzodiazepine Receptors in Recovery from
 Alcohol Dependence: Relationship to Features of Alcohol Dependence and
 Cigarette Smoking. Presentation at the Kunin-Lunenfeld Applied Research
 Unit Rounds. Toronto, ON, Canada, March 30th, 2005.
29. Rapoport MJ, **Verhoeff NPLG**, van Reekum R. Traumatic Brain Injury and
 Dementia Symposium. Presented at the American Association for geriatric
 Psychiatry's 2005 Annual Meeting in San Diego, California, USA, March
 4th, 2005.
30. **Verhoeff NPLG.** Acetylcholine and amyloid: connections between
 cholinergic neurotransmission and the β -amyloid cascade. Presentation at
 Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre
 for Geriatric Care. Toronto, ON, Canada, February 25th, 2005
31. **Verhoeff NPLG.** Agitation and psychotic disorders in the elderly.
 Presentation at the Geriatric Psychiatry Seminar Series at the
 Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care.
 Toronto, ON, Canada, February 7th, 2005.
32. **Verhoeff NPLG.** Cortical GABA_A/Benzodiazepine Receptors in Recovery from
 Alcohol Dependence: Relationship to Features of Alcohol Dependence and
 Cigarette Smoking. Presentation at Rounds at the Department of
 Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON,
 Canada, January 12th, 2005.
33. **Verhoeff NPLG**, Mamelak M. Patient with visual hallucinations.
 Presentation at Rounds at the Department of Behavioural Neurology,
 Baycrest Centre for Geriatric Care. Toronto, ON, Canada, November 24th,
 2004.
34. **Verhoeff NPLG.** Alcohol and substance abuse in the elderly. Presentation
 at the Geriatric Psychiatry Seminar Series at the Department of
 Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON,
 Canada, November 1st, 2004.
35. **Verhoeff NPLG.** Beta-amyloid PET study: second progress report.
 Presentation at the Neuroscience Rounds at Sunnybrook and Women's
 College Health Sciences Centre. Toronto, ON, Canada, October 19th, 2004.
36. **Verhoeff NPLG.** Does hypothyroidism cause Alzheimer's disease?
 Presentation at Evidence Based Clinical Practice Seminars, Baycrest
 Centre for Geriatric Care. Toronto, ON, Canada, October 18th, 2004.
37. **Verhoeff NPLG.** Beta-amyloid PET study: second progress report.
 Presentation at the Schizophrenia Research Seminars at the Centre for
 Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, October
 6th, 2004.
38. **Verhoeff NPLG.** Beta-amyloid PET study: second progress report.
 Presentation at the Kunin-Lunenfeld Applied Research Unit Rounds.
 Toronto, ON, Canada, September 29th, 2004.
39. **Verhoeff NPLG.** Beta-amyloid PET study: second progress report.
 Presentation at Grand Rounds at the Department of Geriatric Psychiatry,
 Baycrest Centre for Geriatric Care. Toronto, ON, Canada, September 24th,

2004.

40. **Verhoeff NPLG.** Agitation and psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, August 9th, 2004.
41. **Verhoeff NPLG.** Beta-amyloid PET study: first progress report. Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, June 30th, 2004.
42. **Verhoeff NPLG.** Beta-amyloid PET study: first progress report. Presentation at the PET Centre Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, June 4th, 2004.
43. **Verhoeff NPLG.** The role of GABA in PTSD: central type benzodiazepine receptors in Gulf war veterans with post-traumatic stress disorder. Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, May 7th, 2004.
44. **Verhoeff NPLG.** Acetylcholine and amyloid: connections between cholinergic neurotransmission and the β -amyloid cascade. Presentation at the Kunin-Lunenfeld Applied Research Unit Rounds. Toronto, ON, Canada, April 14th, 2004.
45. **Verhoeff NPLG.** The role of GABA in depression: cerebral benzodiazepine receptors in depressed patients measured with [¹²³I]iomazenil SPECT. Presentation at the Kunin-Lunenfeld Applied Research Unit Rounds. Toronto, ON, Canada, March 24th, 2004.
46. **Verhoeff NPLG.** Does traumatic brain injury induce cerebral β -amyloidosis and does genetic ApoE status affect this induction? Presentation at Evidence Based Clinical Practice Seminars, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, March 8th, 2004.
47. **Verhoeff NPLG.** Agitation and psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, March 8th, 2004.
48. **Verhoeff NPLG.** The role of GABA in depression: cerebral benzodiazepine receptors in depressed patients measured with [¹²³I]iomazenil SPECT. Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, March 5th, 2004.
49. **Verhoeff NPLG.** Acetylcholine and amyloid: connections between cholinergic neurotransmission and the β -amyloid cascade. Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, March 3rd, 2004.
50. **Verhoeff NPLG,** Wilson AA, Nobrega J, Milgram NW, Westaway D, St. George-Hyslop P, Head E, Hussey D, Takeshita S, Trop L, Tapp D, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at the Rotman Research Institute Rounds. Toronto, ON, Canada, February 9th, 2004.
51. **Verhoeff NPLG,** Meier R, Mangar M, Wilkie T. Management of Agitation and Aggression in the Elderly. Presentation at Psychogeriatric Update 2003 at the Joseph E. and Minnie Wagman Centre, Baycrest Centre for Geriatric Care, Toronto, ON, Canada, November 28th, 2003.
52. **Verhoeff NPLG,** Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson

- L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at the Neuroscience Rounds at Sunnybrook and Women's College Health Sciences Centre. Toronto, ON, Canada, November 20th, 2003.
53. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at the PET Centre Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, November 14th, 2003.
54. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, November 12th, 2003.
55. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, October 31st, 2003.
56. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at the Kunitz-Lunenfeld Applied Research Unit Rounds. Toronto, ON, Canada, October 29th, 2003.
57. **Verhoeff NPLG**. Is it likely that cholinesterase inhibitors (AChEI) decrease A β aggregation in Alzheimer's disease patients? Presentation at Evidence Based Clinical Practice Seminars, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, October 27th, 2003.
58. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at the Schizophrenia Research Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, September 24th, 2003.
59. **Verhoeff NPLG**, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Kung HF, Kung MP, Houle S. [¹¹C]SB-13 PET: a valid alternative for β -amyloid imaging in vivo? Presentation at the VIth International Conference on Quantification of Brain Function with PET organized by the Society for Cerebral Blood Flow and Metabolism, in Calgary, Alberta, Canada, July 2nd, 2003.
60. **Verhoeff NPLG**. Development of positron emission tomography tracers for β -amyloid imaging in vivo and its possible implications for management of Alzheimer's disease. Presentation at the meeting Facilitating the development of PET Diagnostics for Alzheimer's disease, sponsored and organized by the Institute of Aging, Inc., and Amersham Health, Inc., and held at the New York Academy of Sciences. New York, NY, USA, May 2nd, 2003.
61. **Verhoeff NPLG**. AMPT-induced catecholamine depletion in schizophrenic patients and control subjects. Presentation at the Rotman Research Institute Rounds. Toronto, ON, Canada, March 3rd, 2003.

62. **Verhoeff NPLG.** Can beta-amyloid PET assist in the prediction which Mild Cognitive Impairment patients will develop Alzheimer's disease? Presentation at Evidence Based Clinical Practice Seminars, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, March 3rd, 2003.
63. **Verhoeff NPLG.** Psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, March 3rd, 2003.
64. **Verhoeff NPLG.** Beta-amyloid imaging in vivo. Presentation at the Neuro-Geriatric Psychiatry Lecture Series at the Centre for Addiction and Mental Health, Queen Street Site. Toronto, ON, Canada, February 19th, 2003.
65. **Verhoeff NPLG.** Beta-amyloid imaging in vivo. Presentation at the Grand Rounds at Baycrest Centre for Geriatric Care. Toronto, ON, Canada, January 17th, 2003.
66. **Verhoeff NPLG.** AMPT-induced catecholamine depletion in schizophrenic patients and control subjects. Presentation at the Kunin-Lunenfeld Applied Research Unit Rounds. Toronto, ON, Canada, December 18th, 2002.
67. **Verhoeff NPLG.** Do NSAIDs reduce the risk of developing Alzheimer's disease? Presentation at Evidence Based Clinical Practice Seminars, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, November 11th, 2002.
68. **Verhoeff NPLG.** Beta-amyloid imaging in vivo. Presentation at the Kunin Lunenfeld Applied Research Unit 2nd Annual Conference on Alzheimer and Related Dementias: The Prevention of Disease, Morbidity, and Suffering. Toronto, ON, Canada, October 18th, 2002.
69. **Verhoeff NPLG.** AMPT-induced catecholamine depletion in schizophrenic patients and control subjects. Presentation at the Schizophrenia Research Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, September 25th, 2002.
70. **Verhoeff NPLG.** Psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, August 30th, 2002.
71. **Verhoeff NPLG.** Benzodiazepine Receptor Imaging in Geriatric Neuropsychiatric Disorders. Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, June 12th, 2002.
72. **Verhoeff NPLG.** Dopamine depletion in healthy subjects and in schizophrenic patients. Presentation at an Educational Evening of the Behavioural Neurology Section of the Division of Neurology, University of Toronto, ON, Canada, May 29th, 2002.
73. **Verhoeff NPLG.** Psychotic disorders in the elderly. Presentation at the Geriatric Psychiatry Seminar Series at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, April 8th, 2002.
74. **Verhoeff NPLG.** Effects of catecholamine depletion on D₂ receptor binding, mood, attentiveness and personality in humans. Presentation at Grand Rounds at the Department of Geriatric Psychiatry, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, February 8th, 2002.

75. **Verhoeff NPLG**. Effects of catecholamine depletion on D₂ receptor binding, mood, attentiveness and personality in humans. Presentation at Rounds at the Department of Behavioural Neurology, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, February 6th, 2002.
76. **Verhoeff NPLG**. Efficacy and adverse effect rates of antipsychotics for agitation and psychosis in elderly patients with AD. Presentation at Evidence Based Clinical Practice Seminars, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, November 26th, 2001.
77. **Verhoeff NPLG**. Update on presentations at the American College of Neuropsychopharmacology meeting. Presentation at the Schizophrenia Research Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, December 20th, 2000.
78. **Verhoeff NPLG**. Benzodiazepine receptor imaging in neuropsychiatric disorders. Presentation at Rounds at the Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care. Toronto, ON, Canada, August 29th, 2000.
79. **Verhoeff NPLG**. Dopamine depletion in healthy subjects. Presentation at the Schizophrenia Research Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, June 21st, 2000.
80. **Verhoeff NPLG**. Clinical utility of benzodiazepine receptor imaging in vivo. Presentation at Nuclear Medicine Y2K: a better image, Northeast regional Scientific Meeting, organized by the Greater New York and New England Chapters of the Society of Nuclear Medicine. Philadelphia, PA, USA, November 5th, 1999.
81. **Verhoeff NPLG**. GABA_A-benzodiazepine receptors: SPECT and schizophrenia. Presentation at the Schizophrenia Research Seminars at the Centre for Addiction and Mental Health, Clarke Site. Toronto, ON, Canada, September 22nd, 1999.
82. **Verhoeff NPLG**. Present and future clinical indications for neuro receptor imaging studies with SPECT. Presentation at the University Hospital of Gent. Gent, Belgium, Europe, March 23rd, 1994.
83. **Verhoeff NPLG**. SPECT of the dopaminergic system. Jubilee Symposium of the Dutch Society for Nuclear Medicine. Zeist, The Netherlands, Europe, October 29th, 1993.
84. **Verhoeff NPLG**. In vivo imaging of brain dopamine D₂ receptors with [¹²³I]IBZM in Parkinsonian syndromes. Presentation at Expert Meeting Nuclear Medicine in Neurology and Psychiatry organized by the Johannes Gutenberg University Mainz. Mainz, Germany, March 22nd-23rd, 1993.
85. **Verhoeff NPLG**. Methodology of dopamine D₂ receptor imaging in vivo using ¹²³I-iodobenzamide SPECT. Presentation at Symposium Brain SPECT imaging in Psychiatry organized by the Departments of Nuclear Medicine and Psychiatry of the University of Bonn in cooperation with the German Society for Nuclear Medicine. Bonn, Germany, March 13th, 1993.
86. **Verhoeff NPLG**. ¹²³I-IBZM receptor studies. Symposium on Neurology and SPECT by the Dutch Society of Radiological Laboratory Workers. Utrecht, The Netherlands, Europe, February 11th, 1993.
87. Kwa IH, Weinstein HC, Posthumus Meyes FE, Van Royen EA, Bour LJ, **Verhoeff NPLG**, Ongerboer de Visser BW. EEG spectral analysis and SPECT in Alzheimer's disease. Scientific Symposium of the Dutch Society for Clinical Neurophysiology. Utrecht, The Netherlands, Europe, November 16th, 1991.

88. Pelli Noble RF, **Verhoeff NPLG**, Reits D, Spekrijse H. A comparative study of SPECT and EEG brain maps generated by pattern stimulation. Presentation at the 8th Panamerican Neurological Congress. Montevideo, Uruguay, October 6th-12th, 1991.
89. **Verhoeff NPLG**. In vivo imaging of brain D₂ dopamine receptors with [¹²³I]IBZM. SPECT Imaging Seminar at Section on Clinical Brain Imaging, National Institute of Mental Health, Bethesda, MD, USA, June 20th, 1991.
90. **Verhoeff NPLG**. Dopamine receptor imaging with [¹²³I]IBZM SPECT in healthy volunteers using a rotating gamma camera or a brain-dedicated, dynamic NeuroSPECT camera. Lecture at NIMH Neuroscience Center at St. Elizabeth's, Washington, DC, USA, June 19th, 1991.
91. **Verhoeff NPLG**. [¹²³I]IBZM SPECT with a long-bore collimator or old SPECT in the lap of a new future. Scientific Symposium of the Dutch Society for Nuclear Medicine. Amsterdam, The Netherlands, Europe, October 20th, 1990.
92. **Verhoeff NPLG**, Costa DC, Ell PJ, Van Royen EA. Dynamic [¹²³I]IBZM SPECT of Dopamine D₂ receptors. 28th Nuclear Medicine Symposium of the Czechoslovak Society for Nuclear Medicine and Radiation Hygiene. Banská Bystrica, Czechoslovakia, Europe, October 5th, 1990.
93. **Verhoeff NPLG**. SPECT in relation to D₂ receptors. Symposium of PhD graduate students, Netherlands Institute for Brain Research. Amsterdam, The Netherlands, Europe, March 28th, 1990.
94. **Verhoeff NPLG**. Dopamine D₂ receptor imaging with advanced multidetector SPECT equipment. Report Meeting of the Dutch Society for Nuclear Medicine. Amsterdam, The Netherlands, Europe, March 19th, 1990.
95. **Verhoeff NPLG**. Further results with [¹²³I]IBZM, an imaging radioligand for dopamine D₂ receptors. Report Meeting of the Dutch Society for Nuclear Medicine. Amsterdam, The Netherlands, Europe, September 8th, 1989.
96. Bobeldijk M, **Verhoeff NPLG**. [¹²³I]IBZM synthesis for dopamine receptor imaging. Report Meeting of the Dutch Society for Nuclear Medicine. Amsterdam, The Netherlands, Europe, June 11th, 1989.
97. **Verhoeff NPLG**. GABA receptors and epilepsy. Report Meeting of the Dutch Society for Nuclear Medicine. Amsterdam, The Netherlands, Europe, February 20th, 1989.